These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30282359)

  • 1. Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.
    Fiorenzato E; Biundo R; Cecchin D; Frigo AC; Kim J; Weis L; Strafella AP; Antonini A
    J Alzheimers Dis; 2018; 66(1):229-237. PubMed ID: 30282359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson's Disease.
    Oh YS; Yoo SW; Lyoo CH; Yoo JY; Yoon H; Ha S; Lee KS; Kim JS
    J Parkinsons Dis; 2021; 11(2):605-613. PubMed ID: 33646180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study.
    Palermo G; Tommasini L; Aghakhanyan G; Frosini D; Giuntini M; Tognoni G; Bonuccelli U; Volterrani D; Ceravolo R
    J Alzheimers Dis; 2019; 70(2):597-609. PubMed ID: 31256138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
    Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
    Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
    Buongiorno M; Antonelli F; Compta Y; Fernandez Y; Pavia J; Lomeña F; Ríos J; Ramírez I; García JR; Soler M; Cámara A; Fernández M; Basora M; Salazar F; Sanchez-Etayo G; Valldeoriola F; Barrio JR; Marti MJ
    J Alzheimers Dis; 2017; 55(3):1261-1272. PubMed ID: 27814297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment.
    Dao E; Best JR; Hsiung GR; Sossi V; Jacova C; Tam R; Liu-Ambrose T
    BMC Geriatr; 2017 Jun; 17(1):133. PubMed ID: 28659161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia.
    Mashima K; Ito D; Kameyama M; Osada T; Tabuchi H; Nihei Y; Yoshizaki T; Noguchi E; Tanikawa M; Iizuka T; Date Y; Ogata Y; Nakahara T; Iwabuchi Y; Jinzaki M; Murakami K; Suzuki N
    Eur Neurol; 2017; 77(5-6):231-237. PubMed ID: 28285306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of cognitive impairment in patients with Parkinson's disease and its related pattern in
    Wu L; Liu FT; Ge JJ; Zhao J; Tang YL; Yu WB; Yu H; Anderson T; Zuo CT; Chen L; Wang J
    Hum Brain Mapp; 2018 Dec; 39(12):4652-4662. PubMed ID: 29999569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.
    Mihaescu AS; Valli M; Uribe C; Diez-Cirarda M; Masellis M; Graff-Guerrero A; Strafella AP
    Mol Brain; 2022 Sep; 15(1):79. PubMed ID: 36100909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease.
    Zhu SG; Chen ZL; Xiao K; Wang ZW; Lu WB; Liu RP; Huang SS; Zhu JH; Zhang X; Wang JY
    Eur J Med Res; 2024 Jun; 29(1):334. PubMed ID: 38880878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system blockers affect cognitive decline in Parkinson's disease: The PPMI dataset.
    Yang J; Gao Y; Duan Q; Qiu Y; Feng S; Zhan C; Huang Y; Zhang Y; Ma G; Nie K; Wang L
    Parkinsonism Relat Disord; 2022 Dec; 105():90-95. PubMed ID: 36395543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.
    McMillan CT; Wolk DA
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1112-22. PubMed ID: 27288043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.
    Petrou M; Dwamena BA; Foerster BR; MacEachern MP; Bohnen NI; Müller ML; Albin RL; Frey KA
    Mov Disord; 2015 Jun; 30(7):928-35. PubMed ID: 25879534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease.
    Kang JH
    J Mov Disord; 2016 May; 9(2):89-96. PubMed ID: 27240810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical thinning across Parkinson's disease stages and clinical correlates.
    Wilson H; Niccolini F; Pellicano C; Politis M
    J Neurol Sci; 2019 Mar; 398():31-38. PubMed ID: 30682518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.